Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Liver Decompensation Clear all
Terminated No phase listed Observational Accepts healthy volunteers

Eye Movement Testing for Diagnosing Encephalopathy in Patients With Liver Disease

NCT04940416
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
Neurofit (oculometric testing)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 25, 2026, 5:13 AM EDT
Terminated Not applicable Interventional Results available

Procurement of Leukapheresis Products From End Stage Liver Disease (ESLD) Patients for Immunological Studies

NCT02447926
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Leukapheresis
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 25, 2026, 5:13 AM EDT
Completed Not applicable Interventional Results available

A Physical Activity Program in End-state Liver Disease

NCT02776553
View directory record Official record
Conditions
End-stage Liver Disease (ESLD), Liver Transplant, Sarcopenia, Poor Physical Fitness, Cirrhosis, Portal Hypertension
Interventions
Nutritional consultation, Physical training program, Behavioral modification therapy
Other · Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
40 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 25, 2026, 5:13 AM EDT
Completed Phase 1 Interventional

Oral Fecal Transplant in Cirrhosis

NCT03152188
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
FMT, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 25, 2026, 5:13 AM EDT
Completed No phase listed Observational

Assessment of Endothelial Function, Apolipoproteins and Adiponectin

NCT01300390
View directory record Official record
Conditions
Cirrhosis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Sep 25, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Results available

Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection

NCT00163657
View directory record Official record
Conditions
End Stage Liver Disease, Hepatitis C
Interventions
Daclizumub, Tacrolimus, Cyclosporine, MMF
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 25, 2026, 5:13 AM EDT
Completed No phase listed Observational

Correlation Between Release of Cytokines From Liver Graft and Hemodynamic Instability

NCT01120743
View directory record Official record
Conditions
Liver Transplantation
Interventions
Not listed
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 25, 2026, 5:13 AM EDT
Completed Not applicable Interventional Results available

Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study

NCT02635347
View directory record Official record
Conditions
Liver Failure, Carcinoma, Hepatocellular
Interventions
Remote Ischemic Conditioning (RIC), Pneumatic tourniquet
Procedure · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 25, 2026, 5:13 AM EDT
Terminated Phase 2 Interventional

Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose

NCT05517668
View directory record Official record
Conditions
Acetaminophen, Drug Overdose, Acetaminophen Overdose, Acetaminophen Poisoning, Drug-induced Liver Injury, Liver Failure, Liver Toxicity
Interventions
Intravenous infusion of N-acetylcysteine, Intravenous infusion of Fomepizole (4-MP)
Drug
Lead sponsor
Richard Dart, MD, PhD
Other
Eligibility
10 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 25, 2026, 5:13 AM EDT
Terminated Phase 2 Interventional

Quantitative Liver Function Tests Using Cholates

NCT01907074
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Cholates
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 25, 2026, 5:13 AM EDT
Completed No phase listed Observational Results available

Superior Vena Cava and Its Relationship to Central Venous Pressure Measurements in Liver Transplantation

NCT02818218
View directory record Official record
Conditions
Liver Failure
Interventions
Liver Transplant
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 25, 2026, 5:13 AM EDT
Terminated No phase listed Observational

Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure

NCT01582087
View directory record Official record
Conditions
Acute and Chronic Hepatic Failure With Developing Coma
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 25, 2026, 5:13 AM EDT
Terminated Phase 2 Interventional

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

NCT06987968
View directory record Official record
Conditions
Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
Interventions
VS-01 on top of SOC (Active Treatment Group), SOC
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 79 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 25, 2026, 5:13 AM EDT
Completed No phase listed Observational

Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection

NCT03248622
View directory record Official record
Conditions
Hepatitis B
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 25, 2026, 5:13 AM EDT
Completed No phase listed Observational

Transplant Patient Registry of Liver, Kidney and/or Pancreas

NCT00238693
View directory record Official record
Conditions
End Stage Renal Disease, End Stage Liver Disease
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Not listed
Enrollment
13,767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 25, 2026, 5:13 AM EDT
Terminated Phase 2 Interventional Results available

Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning

NCT00915681
View directory record Official record
Conditions
Amatoxin Poisoning, Amanita Poisoning, Mushroom Poisoning, Liver Failure
Interventions
Silibinin
Drug
Lead sponsor
Mylan Specialty, LP
Industry
Eligibility
Not listed
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
Somerset, New Jersey • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Sep 25, 2026, 5:13 AM EDT
Suspended No phase listed Observational

Longitudinal Study of Mitochondrial Hepatopathies

NCT01148550
View directory record Official record
Conditions
Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation
Interventions
Not listed
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2029
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 25, 2026, 5:13 AM EDT
Recruiting Not applicable Interventional

Adverse Outcomes and Mortality in Liver Transplant

NCT05477277
View directory record Official record
Conditions
End Stage Liver DIsease, Sarcopenia, Sarcopenic Obesity, Cirrhosis
Interventions
MAsS
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 25, 2026, 5:13 AM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

NCT01937130
View directory record Official record
Conditions
Acute on Chronic Hepatic Failure, Acute Liver Failure, Liver Cirrhosis, Acute Alcoholic Hepatitis
Interventions
IDN-6556, Placebo
Drug · Other
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced Sep 25, 2026, 5:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome

NCT02083367
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Nonalcoholic Steatohepatitis, Hepatitis C
Interventions
Not listed
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Sep 25, 2026, 5:13 AM EDT
Completed Phase 2Phase 3 Interventional Results available

13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF

NCT02786836
View directory record Official record
Conditions
Acute Liver Failure
Interventions
13C-Methacetin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 25, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

NCT01687257
View directory record Official record
Conditions
Hepatitis C, Cirrhosis, Portal Hypertension, With or Without Liver Decompensation
Interventions
SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Sep 25, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Results available

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

NCT01842581
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
43
States / cities
Phoenix, Arizona • Coronado, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Sep 25, 2026, 5:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study of the Liver Live Donor Champion Program

NCT03580629
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Liver Live Donor Champion Program
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 25, 2026, 5:13 AM EDT